Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R208 and Each Monotherapy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 219 participants.

Also called NCT02770261

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 219 participants (enrolled count) (from the registry)
Sponsor
Alvogen Korea (from the registry)
Registry
  • NCT NCT02770261
Other papers using this trial's data
  • Efficacy and Safety of a Fixed-Dose Combination of Candesartan and Rosuvastatin on Blood Pressure and Cholesterol in Patients With Hypertension and Hypercholesterolemia: A Multicenter, Randomized, Double-Blind, Parallel Phase III Clinical Study Clinical therapeutics, 2019-08 DOI, PubMed 31307833

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02770261. Randomized; double masking; primary purpose treatment. Start 2015-12 (registry gives no type); primary completion 2016-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R208 and Each Monotherapy
Condition
Hypertension
Condition
Cholesterolemia
Intervention (Drug)
DP-R208
Intervention (Drug)
Candesartan32mg
Intervention (Drug)
Rosuvastatin 20mg
Intervention (Drug)
DP-R208 Placebo
Intervention (Drug)
Candesartan32mg Placebo
Intervention (Drug)
Rosuvastatin 20mg Placebo
Lead sponsor
Alvogen Korea (class: industry)

Record details

Record id
cardio:ct-nct02770261
Content hash
830756300f03c106f2268ea26384866f46f2bb55fa5bf9b19052b97ca8a968c1